about
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenibAdjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysisPersonalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisThe progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours.Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST).Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting.Efficacy of weekly docetaxel in locally advanced cardiac angiosarcomaSDHC methylation in gastrointestinal stromal tumors (GIST): a case report.Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST).Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS)Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy.Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives.Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST.Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review).Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy.New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and future.An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST).Treatments for gastrointestinal stromal tumors that are resistant to standard therapies.miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers.Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction.The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs).Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors.Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma.Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor.Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours.Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report.Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib.Liquid biopsy in gastrointestinal stromal tumors: a novel approach.Unusual finding of benign Abrikossoff tumor by F-18 FDG-PET mimicking melanoma recurrence.Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target.A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number.Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up.Microscopic margins of resection influence primary gastrointestinal stromal tumor survival.Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.To widen the setting of cancer patients who could benefit from metronomic capecitabine.The Response Evaluation Criteria in Solid Tumors: until when?
P50
Q21261282-D88AD590-0D7F-48B3-ACF3-AF7B7438F0A7Q26774704-1608D696-9C4E-465D-8F82-F1B3644EE759Q26800005-E0C9D308-F886-4CA0-A51A-745933E71AF7Q33722723-83FA7923-6168-4C98-A3D8-E8E813E447D7Q34141825-AA1AF8A0-97C2-4681-B4D6-9360B50D476BQ34274467-2E51D04A-0EAE-4CDB-B70B-14892B3D5EF6Q34499075-295BEE44-3758-4559-8128-49189161473CQ34629408-14B21338-E719-43E1-90BD-5C87C95FDD9CQ35724800-1880FF26-5B86-480C-BA5B-B7DB9F7F2A2DQ35790835-B381E5CE-4EB6-4338-B90F-8A593BB966E2Q35831238-0D750B5A-2ED4-460D-A7A1-B1DB50B214FDQ36086354-B22004A9-C1B7-4182-B5B3-EF57432C43A7Q36561734-95912BB6-83F7-421D-A858-1E28BCC4DA89Q36695209-F808A6BB-A3AF-462C-B25B-FABAE732F7E0Q37022553-AC3CD00C-AE38-4637-9E74-4E805F6A6B5DQ37350278-4076FB21-0BB0-431B-82EB-FCAAE2795B11Q37397647-B66E8261-798E-45C2-AEAB-F120A3BC31A0Q37474435-65DD7746-4001-4681-A7C2-3BD443B0F549Q37633233-F3283280-FA68-4CA6-8E8A-6CE7DC9DE46CQ37850810-BD5E963A-0ED5-47CF-94C2-BC6A7F414FC0Q38119931-5A8519F0-05D2-4527-8AEF-DBCFC5986E96Q38268165-B65FB5AD-313F-42E4-BC86-D9017E52A2C1Q38602174-4F278836-39DF-4C47-92B6-DA0B4EE6FD4BQ39500990-3EE1CBCD-D20F-4DB9-A5D6-C49297ECA248Q39817075-9D327621-632A-4E7F-9EFB-946A95AF4AB8Q40155361-38308A76-2AE5-47C4-935F-7E718579F36EQ40527891-84F52C70-EE98-42C3-AD50-202939BF4653Q41282761-ECA3D17E-8A57-4159-8BFA-E70AEBCB5194Q41818939-AD8600BE-8490-408D-A840-63804E7A3761Q41994931-83FA338E-4A9E-4558-B3E7-11BC5F7EE2F3Q42061300-1631662D-5CB3-4FF7-B6FF-E419DE2A8FD9Q42560645-572D8E7B-7ABE-421F-A21D-8C704C128CC8Q43247494-E698A6F1-D825-4643-B361-5AB98EBC2BDBQ43293512-AEB3855C-EECE-4DDB-BD59-EDA0FBC7F1BCQ43465485-7245CC86-AEFF-4E6A-BE46-CD58773FDA84Q43735786-DAC82D48-89BE-490F-9228-6032F39F3CABQ44894190-C8363AAC-E8E1-4104-8AF5-C7CDD0195E43Q45180974-C2DBE417-BB72-4079-8859-06F56AC82671Q46158087-A953F6C1-787F-4855-833C-7ECC6CD0E500Q53365721-0A67AF63-05B9-4D5B-A81B-FDDFD46BDFFA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Margherita Nannini
@ast
Margherita Nannini
@en
Margherita Nannini
@es
Margherita Nannini
@nl
type
label
Margherita Nannini
@ast
Margherita Nannini
@en
Margherita Nannini
@es
Margherita Nannini
@nl
prefLabel
Margherita Nannini
@ast
Margherita Nannini
@en
Margherita Nannini
@es
Margherita Nannini
@nl
P106
P1153
23974748700
P31
P496
0000-0002-2103-1960